Altoida is a pioneering brand revolutionizing the way brain health is assessed and measured. With their advanced technology platform, they develop digital biomarkers of neurological disease using augmented reality and machine learning. Altoida's objective evaluation tools can help identify cognitive and functional impairment, symptomatic deficits due to amyloid pathology, and potential progression to Alzheimer's disease.

Their evidence-based platform is built on over 20 years of scientific research and has been published in reputable journals such as Nature Digital Medicine and Alzheimers & Dementia. Altoida aims to enable earlier diagnosis, faster patient inclusion in clinical trials, and sensitive monitoring of disease progression and treatment response. Their vision is to transform neurological care by providing precision brain diagnosis at scale, facilitating faster clinical trials, improving access to breakthrough treatments, and aiding in earlier decision-making for patients and their loved ones.

Please note that Altoida's platform is currently intended for investigational use only and has not received FDA clearance or approval. Contact Altoida at their Washington, DC location or through their website for more information